Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 24, 2018

A series of aggregated randomized-controlled N-of-1 trials with mexiletine in non-dystrophic myotonia: clinical trial results and validation of rare disease design (P3.440)

Bas Stunnenberg, Joost Raaphorst, Hans Groenewoud, Jeffrey Statland, Robert Griggs, Willem Woertman, Dick Stegeman, Janneke Timmermans, Jaya Trivedi, Emma Matthews, Christiaan Saris, Bas Schouwenberg, Gea Drost, Baziel van Engelen, GertJan van der Wilt
First published April 9, 2018,
Bas Stunnenberg
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost Raaphorst
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Groenewoud
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Statland
2University of Kansas Medical Center Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Griggs
3University of Rochester Medical Center Rochester NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willem Woertman
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dick Stegeman
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janneke Timmermans
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaya Trivedi
4UT Southwestern Medical Center Dallas TX United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Matthews
5MRC Centre for Neuromuscular Diseases London United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiaan Saris
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bas Schouwenberg
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gea Drost
6University Medical Centre Groningen Groningen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Baziel van Engelen
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GertJan van der Wilt
1Radboud University Medical Center Nijmegen Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A series of aggregated randomized-controlled N-of-1 trials with mexiletine in non-dystrophic myotonia: clinical trial results and validation of rare disease design (P3.440)
Bas Stunnenberg, Joost Raaphorst, Hans Groenewoud, Jeffrey Statland, Robert Griggs, Willem Woertman, Dick Stegeman, Janneke Timmermans, Jaya Trivedi, Emma Matthews, Christiaan Saris, Bas Schouwenberg, Gea Drost, Baziel van Engelen, GertJan van der Wilt
Neurology Apr 2018, 90 (15 Supplement) P3.440;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: We aimed to validate the aggregated N-of-1 trials design using the case of mexiletine treatment in non-dystrophic myotonia.

Background: In rare diseases it is difficult to achieve level 1 evidence of treatment efficacy due to small cohorts and clinical heterogeneity. With emerging treatments for rare diseases, validation of innovative trial designs is urgently needed.

Design/Methods: We performed a series of aggregated, double-blind, randomized-controlled N-of-1-trials (mexiletine versus placebo) in 30 patients with non-dystrophic myotonia. The primary outcome measure was daily-reported muscle stiffness on a 1–9 scale, with higher scores indicating more impairment. Secondary outcomes included quality of life, myotonia and safety measures.

A Bayesian hierarchical model combined individual N-of-1 trial results into the probability of reaching a clinically meaningful effect ( ≥ 0.75 difference on the primary outcome measure). To assess our trial design validity, we compared our results head-to-head with a previously conducted RCT. Eligibility criteria, treatment regimen, end-points and assessments were fully compatible between trials.

Results: In 24 of the 27 patients who completed their N-of-1 trial, a clinically meaningful treatment effect was found. Mexiletine resulted in a mean muscle stiffness reduction of 3.06 (n=27, 95% credible interval 1.96–4.15). Adverse reactions included gastro-intestinal complaints (70%). The evidence that mexiletine reduces myotonia with a meaningful difference, with 95% probability, was reached after the first 11 consecutive patients. Meta-analysis of aggregated N-of-1 trials and RCT results showed absence of statistical heterogeneity (I2 = 0%) on the primary outcome measure. Secondary outcomes and adverse reactions profiles were comparable between trials.

Conclusions: Our data show that aggregated N-of-1 trials produce a valid estimate of treatment effect at the group level. Compared to conventional designs, this trial approach seems promising with regard to efficiency and when dealing with patient heterogeneity. Furthermore, our data strengthen the evidence of mexiletine as a safe and effective treatment in non-dystrophic myotonia.

Study Supported by:

ZonMw, The Netherlands Organisation for Health Research and Development (Project number: 152002029)

Disclosure: Dr. Stunnenberg has nothing to disclose. Dr. Raaphorst has nothing to disclose. Dr. Groenewoud has nothing to disclose. Dr. Statland has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strongbridge, Acceleron, Regeneron, and Sanofi. Dr. Griggs has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Serve on DSMB for PTC Therapeutics, Idera Pharma; consultant for Saretpta, Marathon, Strongbridge and Taro Pharma. Dr. Griggs has received personal compensation in an editorial capacity for Correspondence editor for Neurology. Dr. Griggs has received royalty, license fees, or contractual rights payments from Royalties from Marathon and PTC Pharmaceuticals. Dr. Griggs has received research support from Research support from Marathon, PTC. Dr. Woertman has nothing to disclose. Dr. Stegeman has nothing to disclose. Dr. Timmermans has nothing to disclose. Dr. Trivedi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi. Dr. Trivedi has received research support from Sanofi, CSL Behring. Dr. Matthews has nothing to disclose. Dr. Saris has nothing to disclose. Dr. Schouwenberg has nothing to disclose. Dr. Drost has nothing to disclose. Dr. van Engelen has nothing to disclose. Dr. van der Wilt has nothing to disclose.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise